HELIX DIAGNOSTICS
Pharmacogenomics (PGx) APOE Panel
Panel Description
Lecanemab-irmb and donanemab-azbt are prescribed for patients with mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease (AD) in order to slow the progression of MCI due to AD and mild AD dementia. APOE ε4 homozygotes have an increased risk for adverse events.
This test evaluates a patient’s APOE status, which can aid in appropriate prescription of lecanemab-irmb and donanemab-azbt.
Genes Tested (1)
Important Panel Information
Turnaround time: 7-10 days
Preferred specimen: BD Vacutainer Whole Blood K2 EDTA Collection Tube 4mL or Oragene Dx Saliva Collection Kit
Shipping Instructions: Specimens to arrive at Helix within 96 hours of collection at ambient temperature.
Mild cognitive impairment (MCI) or mild dementia stage of Alzheimer's disease.
All detected variants are evaluated according to the Clinical Pharmacogenetics Implementation Consortium (CPIC). Variants are classified based on known, predicted, or possible impact on drug metabolism.